• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - May 23, 2022 Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research

The Impact of Metformin Use on the Cardiovascular Effects of DPP ‐4 Inhibitors: an Analysis of Medicare Claims Data 2007‐2015
ConclusionsIncidence rate differences in multiple cardiovascular outcomes appeared more favorable when DPP ‐4i initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4i and metformin.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - November 20, 2018 Category: Endocrinology Authors: Matthew J. Crowley, Mugdha Gokhale, Virginia Pate, Til St ürmer, John B. Buse Tags: ORIGINAL ARTICLE Source Type: research

Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes
ConclusionsIn veterans with Type 2 diabetes, greater HbA1c variability was associated with an increased risk of adverse long‐term outcomes, independently of HbA1c levels and direction of change. Limiting HbA1c fluctuations over time may reduce complications.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - June 8, 2016 Category: Endocrinology Authors: J. C. Prentice, S. D. Pizer, P. R. Conlin Tags: Research Article Source Type: research